GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » Days Sales Outstanding

Zogenix (Zogenix) Days Sales Outstanding : 33.65 (As of Dec. 2021)


View and export this data going back to 2010. Start your Free Trial

What is Zogenix Days Sales Outstanding?

Zogenix's average Accounts Receivable for the three months ended in Dec. 2021 was $9.81 Mil. Zogenix's Revenue for the three months ended in Dec. 2021 was $26.61 Mil. Hence, Zogenix's Days Sales Outstanding for the three months ended in Dec. 2021 was 33.65.

The historical rank and industry rank for Zogenix's Days Sales Outstanding or its related term are showing as below:

ZGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.19   Med: 74.19   Max: 467.43
Current: 33.3

During the past 13 years, Zogenix's highest Days Sales Outstanding was 467.43. The lowest was 31.19. And the median was 74.19.

ZGNX's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 72.245 vs ZGNX: 33.30

Zogenix's Days Sales Outstanding increased from Dec. 2020 (27.55) to Dec. 2021 (33.65).


Zogenix Days Sales Outstanding Historical Data

The historical data trend for Zogenix's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix Days Sales Outstanding Chart

Zogenix Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 467.43 - - 102.31 31.19

Zogenix Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.55 33.15 33.56 34.68 33.65

Competitive Comparison of Zogenix's Days Sales Outstanding

For the Biotechnology subindustry, Zogenix's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zogenix's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zogenix's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Zogenix's Days Sales Outstanding falls into.



Zogenix Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Zogenix's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

Days Sales Outstanding (A: Dec. 2021 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2020 ) + Accounts Receivable (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )*Days in Period
=( (3.824 + 10.139) / 2 ) / 81.69*365
=6.9815 / 81.69*365
=31.19

Zogenix's Days Sales Outstanding for the quarter that ended in Dec. 2021 is calculated as:

Days Sales Outstanding (Q: Dec. 2021 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2021 ) + Accounts Receivable (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )*Days in Period
=( (9.486 + 10.139) / 2 ) / 26.608*365 / 4
=9.8125 / 26.608*365 / 4
=33.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zogenix  (NAS:ZGNX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Zogenix Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Zogenix's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Zogenix (Zogenix) Business Description

Traded in Other Exchanges
N/A
Address
5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Executives
Erle T Mast director C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner director PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick director C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts director C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar officer: EVP & CHIEF COMMERCIAL OFFICER C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel officer: EVP/Chief Development Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer officer: EVP/Chief Medical Officer C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr director, officer: President and CEO [email protected] EMERYVILLE CA 94608
Mark C Wiggins director 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock director C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer director
Shawnte Mitchell officer: EVP, GC and Secretary 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith officer: EVP, CFO, Treasurer & Sec. 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5

Zogenix (Zogenix) Headlines

From GuruFocus

Zogenix Reports Granting of Inducement Awards

By GlobeNewswire GlobeNewswire 09-16-2021